Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled date : 2022 - 05 - 16 source : Www.biospace.com save search
Compugen Reports First Quarter 2022 Results
Published: 2022-05-16 (Crawled : 21:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 8.81%
H: 1.9%
C: -6.67%
results
Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting
Published: 2022-05-16 (Crawled : 21:00) - biospace.com/
ATHA | $2.12 2.91% 2.83% 200K
|
Health Technology
|
| O: 2.12%
H: 7.44%
C: 5.73%
pharma preclinical pre-clinical
Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
Published: 2022-05-16 (Crawled : 20:00) - biospace.com/
VERA | $37.96 -3.85% -4.0% 1.4M
|
Professional, Scientific, and T...
|
| O: -1.44%
H: 7.43%
C: 5.04%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -0.4%
H: 2.5%
C: 1.3%
therapeutics results
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer
Published: 2022-05-16 (Crawled : 20:00) - biospace.com/
URGN | $13.78 -3.37% -3.48% 390K
|
Health Technology
|
| O: -1.18%
H: 0.0%
C: -4.93%
jelmyto treatment cancer kidney
RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus
Published: 2022-05-16 (Crawled : 19:00) - biospace.com/
RSPI | $0.0008 0.0% 600K
|
Manufacturing
|
| O: 7.27%
H: 5.08%
C: -5.08%
treatment review potential publication
Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting
Published: 2022-05-16 (Crawled : 19:00) - biospace.com/
CDXS | $2.815 0.54% 0.53% 470K
|
Process Industries
|
| O: -1.55%
H: 1.57%
C: -5.74%
pre-clinical therapy preclinical
Impel Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-05-16 (Crawled : 19:00) - biospace.com/
IMPL 4 | $0.2411 -77.19% 860K
|
Professional, Scientific, and T...
|
| O: 0.77%
H: 6.3%
C: 4.15%
results
aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
Published: 2022-05-16 (Crawled : 19:00) - biospace.com/
LIFE | $1.6 -1.23% -1.25% 160K
|
Health Technology
|
| O: 0.0%
H: 5.23%
C: 0.65%
atyr1923 pharma phase 3
Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization
Published: 2022-05-16 (Crawled : 19:00) - biospace.com/
AMLX A | $1.88 -5.05% -5.32% 2.5M
|
|
| O: -0.83%
H: 2.57%
C: -0.6%
amx0035 publication
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors
Published: 2022-05-16 (Crawled : 19:00) - biospace.com/
CCCC | $6.74 -2.46% -2.52% 1.7M
|
Health Technology
|
| O: -1.54%
H: 2.27%
C: -4.69%
cft8634 treatment trial therapeutics phase 1
Positive Clinical Results Advance Treatments For Multiple Myeloma, Asthma, Alzheimer’s
Published: 2022-05-16 (Crawled : 17:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
alzheimer’s positive treatment alzheimer's
Positive Clinical Results Advance Treatments For Multiple Myeloma, Asthma, Al...
Published: 2022-05-16 (Crawled : 17:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
positive treatment
Exciting Advancements in Multiple Myeloma, Asthma and Alzheimer’s
Published: 2022-05-16 (Crawled : 17:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
alzheimer’s alzheimer's
ASGCT Opening Highlights Advancements, New Therapies
Published: 2022-05-16 (Crawled : 17:00) - biospace.com/
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: -2.14%
H: 14.38%
C: 10.63%
therapy
Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update
Published: 2022-05-16 (Crawled : 15:20) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M
|
Health Technology
|
| O: -1.0%
H: 3.16%
C: -1.77%
FBRX 4 | $0.78 5.13% 8.3K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -8.9%
results
Virpax Pharmaceuticals Reports 2022 First Quarter Results and Recent Developments
Published: 2022-05-16 (Crawled : 15:00) - biospace.com/
VRPX | $3.86 -4.46% -4.66% 6K
|
|
| O: 5.22%
H: 3.13%
C: -8.51%
virpax results
Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo® (cemiplimab) in KRAS-Driven Tumors
Published: 2022-05-16 (Crawled : 15:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
eli-002 libtayo therapeutics
INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing
Published: 2022-05-16 (Crawled : 15:00) - biospace.com/
INBX | $34.36 -0.26% -0.26% 220K
|
Health Technology
|
| O: -1.83%
H: 1.2%
C: -17.44%
inbrx-101 potential
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
Published: 2022-05-16 (Crawled : 15:00) - biospace.com/
BIOT | $10.15 -0.78% -0.2% 44K
|
|
| O: 0.1%
H: 0.05%
C: 0.0%
conference preclinical cudetaxestat therapeutics international pre-clinical phase 1
Reaction Biology Announces Expansion of Executive Leadership Team with Key Appointments in Commercial and Human Resources Functions
Published: 2022-05-16 (Crawled : 15:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.95%
H: 0.0%
C: 0.0%
expansion commercial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.